Keyphrases
Adverse Effects
100%
Methylphenidate
100%
Carboxylesterase 1 (CES1)
100%
Attention Deficit Hyperactivity Disorder
37%
Weight-based Dose
37%
Inclusion Criteria
25%
Final Weight
25%
Pharmacokinetics-pharmacodynamics (PK-PD)
12%
Clinical Data
12%
Pharmacogenetics
12%
Weight Loss
12%
Non-responders
12%
Electronic Health Records
12%
Sleep Problems
12%
Drug Interactions
12%
Sequence Data
12%
Stimulants
12%
Retrospective Cohort Study
12%
Healthcare Professionals
12%
Adverse Events
12%
Dose Requirement
12%
Multiple Testing
12%
Copy number
12%
Small Sample Size
12%
Decreased Appetite
12%
Children with Attention Deficit
12%
Saliva Samples
12%
Diplotype
12%
Variability in Response
12%
Weight-based Dosing
12%
Medication Response
12%
Fair Proportion Index
12%
Disorders Diagnosis
12%
Low Weight
12%
Attention-deficit Hyperactivity Disorder Symptoms
12%
Routine Visits
12%
Neuroscience
Adverse Effect
100%
Methylphenidate
100%
Carboxylesterase
100%
Attention Deficit Hyperactivity Disorder
50%
Haplotype
37%
Analeptic
12%
Pharmacokinetics
12%
Pharmacology, Toxicology and Pharmaceutical Science
Methylphenidate
100%
Carboxylesterase
100%
Attention Deficit Disorder
50%
Pharmacodynamics
12%
Cohort Study
12%
Pharmacogenetics
12%
Drug-Drug Interaction
12%
Adverse Event
12%
Decreased Appetite
12%
Pharmacokinetics
12%
Immunology and Microbiology
Haplotype
100%
Drug-Drug Interaction
33%
Pharmacodynamics
33%
Pharmacogenetics
33%
Sample Size
33%
Electronic Health Record
33%
Pharmacokinetics
33%
Biochemistry, Genetics and Molecular Biology
Carboxylesterase 1
100%
Haplotype
50%
Cohort Study
16%
Pharmacogenetics
16%
Pharmacodynamics
16%
Drug Interaction
16%
Sample Size
16%
Electronic Health Record
16%
Pharmacokinetics
16%
Psychology
Methylphenidate
100%
Attention Deficit Hyperactivity Disorder
50%